Emerald Bioventures reports Galera insider stake
Galera Therapeutics, Inc. reported initial insider holdings for Emerald Bioventures, LLC and Timothy Opler as 10% owners.
Rhea-AI Filing Summary
Galera Therapeutics, Inc. reported initial insider holdings for Emerald Bioventures, LLC and Timothy Opler as 10% owners. Emerald directly holds 40,216,160 shares of Common Stock and 20,813.818619 shares of Series B Non-Voting Convertible Preferred Stock. Each Series B share is convertible, at the board’s discretion, into 1,000 shares of Common Stock, totaling 20,813,818.6 underlying Common shares, and has no expiration date. Opler is Emerald’s managing member and may be deemed to beneficially own the securities held by Emerald.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Emerald Bioventures, LLC, Opler Timothy
Role
10% Owner | 10% Owner
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| holding | Series B Preferred Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Holdings After Transaction:
Series B Preferred Stock — 20,813,818.6 contracts (Direct);
Common Stock — 40,216,160 shares (Direct)
Footnotes (2)
- F1. This Form 3 is jointly filed by and on behalf of each of Emerald Bioventures, LLC ("Emerald") and Timothy Opler ("Mr. Opler"). Emerald is the record and direct beneficial owner of the securities reported herein. Timothy Opler is the managing member of Emerald and may be deemed to beneficially own securities owned by Emerald.
- F2. Represents 20,813.8186192892 shares of Series B Non-Voting Convertible Preferred Stock ("Series B Preferred Stock") of the Issuer. On February 12, 2026, the Issuer filed a Certificate of Amendment (the "Amendment") to the Certificate of Designation of Preferences, Rights, and Limitations of Series B Non-Voting Convertible Preferred Stock. The Amendment provided that, in the sole discretion of the Issuer's board of directors, the Issuer may elect to convert, in whole or in part, outstanding shares of Series B Preferred Stock into a number of shares of the Issuer's Common Stock ("Common Stock") calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock issuable upon the conversion of each share of Series B Preferred Stock). The shares of Series B Preferred Stock have no expiration date.
Key Figures
Common Stock held: 40,216,160 shares
Series B Preferred held: 20,813.818619 shares
Conversion Ratio: 1,000 Common shares per Series B share
+2 more
5 metrics
Common Stock held
40,216,160 shares
Directly owned by Emerald Bioventures as of Form 3
Series B Preferred held
20,813.818619 shares
Series B Non-Voting Convertible Preferred Stock held by Emerald
Conversion Ratio
1,000 Common shares per Series B share
Defined in Certificate of Amendment filed February 12, 2026
Underlying Common shares
20,813,818.6 shares
Common Stock issuable upon conversion of Emerald’s Series B Preferred
Series B exercise price
$0.0000 per share
Conversion or exercise price for Series B Preferred Stock
Key Terms
Series B Non-Voting Convertible Preferred Stock, Conversion Ratio, beneficial owner, ten percent owner
4 terms
Series B Non-Voting Convertible Preferred Stock financial
"Represents 20,813.8186192892 shares of Series B Non-Voting Convertible Preferred Stock"
A Series B non-voting convertible preferred stock is a class of company shares that gives holders financial priority—such as fixed dividends and first claim on assets if the company is sold—while not granting voting rights. It can be converted into regular common shares under set conditions, which matters to investors because conversion can increase upside participation but also dilute existing owners; the preference reduces downside risk like a safety buffer.
Conversion Ratio financial
"calculated based on the Conversion Ratio (defined as 1,000 shares of Common Stock"
The conversion ratio is the number of common shares an investor receives when a convertible security (like a bond or preferred share) or an exchangeable instrument is turned into ordinary stock. It matters because it tells investors how much ownership or dilution will occur — similar to knowing how many slices you get when you trade in a coupon — and directly affects the value you get from the convertible and the company’s future share count.
beneficial owner financial
"Emerald is the record and direct beneficial owner of the securities reported herein"
A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.
ten percent owner financial
"is_ten_percent_owner": 1"
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What insider position does Emerald Bioventures hold in Galera Therapeutics (GRTX)?
Emerald Bioventures directly holds 40,216,160 shares of Galera Therapeutics Common Stock. It also owns 20,813.818619 shares of Series B Non-Voting Convertible Preferred Stock, which are convertible into 20,813,818.6 Common shares, giving Emerald a substantial equity stake in the company.
What is the conversion feature of Galera Therapeutics (GRTX) Series B Preferred Stock?
Each share of Galera’s Series B Non-Voting Convertible Preferred Stock is convertible into 1,000 shares of Common Stock. The issuer’s board of directors may, at its sole discretion, elect to convert outstanding Series B shares into Common Stock based on this Conversion Ratio.
Does the Galera Therapeutics (GRTX) Series B Preferred Stock have an expiration date?
The Series B Non-Voting Convertible Preferred Stock of Galera Therapeutics has no expiration date. This means the preferred shares, and their conversion feature into Common Stock, remain outstanding unless converted, redeemed, or otherwise changed according to the company’s governing documents.
AI-generated analysis. How Rhea-AI works. Not financial advice.
